Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Acute myeloid leukemia (AML) is a heterogeneous clonal disease of hematopoietic progenitor cells and the most common malignant myeloid disease in adults. Although significant progress has been made in treatment, the outlook remains bleak, and new therapeutic targets need to be sought. AP-2 complex subunit mu (AP2M1) is a core component of the clathrin-mediated endocytic machinery, AP2M1 plays a critical role in cancer progression. However, its function in acute myeloid leukemia (AML) progression remains unclear. Our study reveals that AP2M1 is highly expressed in AML and is associated with poor prognosis. Mechanistic studies suggest that this effect may result through cell cycle arrest and is associated with the tumor microenvironment, and our findings suggest that AP2M1 is a potential oncogene and prognostic marker for AML.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2025.2504161DOI Listing

Publication Analysis

Top Keywords

acute myeloid
12
myeloid leukemia
12
prognostic marker
8
cell cycle
8
cycle arrest
8
leukemia aml
8
ap2m1
5
ap2m1 prognostic
4
marker associated
4
associated cell
4

Similar Publications

Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.

Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.

View Article and Find Full Text PDF

Acute leukaemias are the commonest cancers in children and young people (CYP). Off-treatment surveillance is assumed to improve relapse detection, but whether this affects subsequent survival and quality of life is unclear. This systematic review searched 13 databases and two trial registries in December 2022.

View Article and Find Full Text PDF

Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 mA modification.

Mol Ther

September 2025

Xi'an No. 1 Hospital, First Affiliated Hospital of Northwest University, School of Medicine, Xi'an, China; Key Laboratory of Resource Biology and Biotechnology of Western China, Ministry of Education; Provincial Key Laboratory of Biotechnology, College of Life Sciences, Northwest University, Xi'an,

N6-methyladenosine (mA) modification, primarily regulated by methyltransferase-like protein 3 (METTL3), plays a pivotal role in RNA metabolism and leukemogenesis. However, the post-translational mechanisms governing METTL3 stability and function remain incompletely understood. Given the widespread occurrence of O-GlcNAcylation on nuclear and cytosolic proteins, we hypothesized that METTL3 might undergo O-GlcNAcylation, thereby influencing its stability and oncogenic function in myeloid malignancies.

View Article and Find Full Text PDF

Background: Benzene, a ubiquitous industrial chemical, is a well-established environmental toxin associated with hematological disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which are characterized by impaired hematopoiesis and bone marrow failure. This study investigates the role of ferroptosis, an iron-dependent form of cell death, in benzene-induced hematotoxicity, focusing on the repression of glutathione peroxidase 4 (GPX4), a critical regulator of ferroptosis.

Materials And Methods: Male C57BL/6 mice were exposed to benzene at various doses over six weeks.

View Article and Find Full Text PDF